Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III randomized double-blind multicenter study of pegylated human G-CSF versus daily G-CSF for prevention of chemotherapy-induced neutropenia
ChiCTR-TRC-12002980Phase 3Completed
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
- Start
- Dec 2011
- Modality
- Recombinant Proteins and Enzymes, Cytokines & Interferons → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of pegfilgrastim and filgrastim in chemotherapy-induced neutropenia (CIN) (3 arms), sponsored by Cancer Institute and Hospital, Chinese Academy of Medical Sciences. Primary endpoint: Duration of grade 3 or 4 neutropenia. Started Dec 2011; status: completed.
02
Drugs
pegfilgrastimfilgrastim
03
Conditions
chemotherapy-induced neutropenia (CIN)
Beyond the preview
Go deeper on ChiCTR-TRC-12002980.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR-TRC-12002980.